Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine for Sympathetic Inhibition in PCOS
NCT01504321Phase 4Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- May 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing Moxonidine with Placebo (2 arms). Primary endpoints: Multiunit muscle sympathetic activity at 3 months and Plasma noradrenaline levels at 3 months. Started May 2012; status: completed.
02
Drugs
moxonidine
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT01504321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01504321.